Can recombinant human TNK treat cerebral infarction?
Recombinant human TNK refers to recombinant human TNK tissue-type plasminogen activator for injection. Under normal circumstances, recombinant human TNK tissue-type plasminogen activator for injection can be used to treat cerebral infarction, and if necessary, should be used under the guidance of a physician. The detailed explanation is as follows:
Recombinant human TNK tissue-type plasminogen activator for injection activates fibrin and promotes the conversion of plasminogen into active plasmin, thereby breaking down fibrin and achieving thrombolysis. This process plays an important role in removing blood clots from the cerebral blood vessels of patients with cerebral infarction, effectively restoring cerebral blood supply and alleviating ischemic symptoms.
In addition, recombinant human TNK tissue-type plasminogen activator for injection can also promote vascular recanalization. After a cerebral infarction, cerebral blood vessels are often blocked by blood clots, interrupting blood flow and leading to ischemic necrosis of brain tissue. By dissolving the blood clots, recombinant human TNK tissue-type plasminogen activator for injection can reopen the occluded vessels, restore normal blood flow, and thus provide essential nutrients and oxygen to the damaged brain tissue, aiding in the recovery of neurological function.
Due to the thrombolytic effect of this drug, it may increase the risk of bleeding. Therefore, patients should undergo regular coagulation function tests during treatment, and seek immediate medical attention if any signs of bleeding occur.